Key facts
- This page summarizes Shalini Sharp's Form 4 filing for Organon & Co. (OGN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 08 Jun 2021, 20:31.
Shalini Sharp - 04 Jun 2021 Form 4 Insider Report for Organon & Co. (OGN)
- Reporting relationship
- Director
- Issuer ticker
- OGN
- Reported as of
- 04 Jun 2021
- Net transaction value
- +$326,649
- SEC form
- 4
- Accepted by SEC
- 08 Jun 2021, 20:31:44 UTC
- Prior SEC filing
- 07 Jun 2021
- Next SEC filing
- 18 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Faye C. Brown, as Attorney-in-Fact for Shalini Sharp
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Shalini Sharp filed Form 4 for Organon & Co. (OGN) on 08 Jun 2021.
Change
- Previous filing in this sequence was filed on 07 Jun 2021.
- Current net transaction value: +$326,649.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2
- Date
- 04 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OGN
transaction
Derivative
Phantom Stock
Award
- Transaction value
- $326,649
- Shares
- +9,061
- Change %
- Price
- $36.05
- Shares after
- 9,061
- Date
- 04 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,061
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Shares acquired in a pro rata distribution by Merck & Co., Inc. ("Merck") of shares of Organon & Co. ("Organon") in connection with the separation of Organon from Merck (the "Separation").
Footnote F2
1-for-1
Footnote F3
Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,512 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases.